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Abstract
Background: Randomized trials comparing VATS lobectomy to open lobectomy are of small size. We analyzed a
case-control series using propensity score-weighting to adjust for important covariates in order to compare the
clinical outcomes of the two techniques.
Methods: We compared patients undergoing lobectomy for clinical stage I lung cancer (NSCLC) by either VATS or
open (THOR) methods. Inverse probability of treatment weighted estimators, with weights derived from propensity
scores, were used to adjust cohorts for determinants of perioperative morbidity and mortality including age,
gender, preop FEV1, ASA class, and Charlson Comorbidity Index (CCI). Bootstrap methods provided standard errors.
Endpoints were postoperative stay (LOS), chest tube duration, complications, and lymph node retrieval.
Results: We analyzed 136 consecutive lobectomy patients. Operative mortality was 1/62 (1.6%) for THOR and 1/74
(1.4%) for VATS, P = 1.00. 5/74 (6.7%) VATS were converted to open procedures. Adjusted median LOS was 7 days
(THOR) versus 4 days (VATS), P < 0.0001, HR = 0.33. Adjusted median chest tube duration (days) was 5 (THOR)
versus 3 (VATS), P < 0.0001, HR = 0.42. Complication rates were 39% (THOR) versus 34% (VATS), P = 0.61. Adjusted
mean number of lymph nodes dissected per patient was 18.1 (THOR) versus 14.8 (VATS), p = 0.17.
Conclusions: After balancing covariates that affect morbidity, mortality and LOS in this case-control series using
propensity-weighting, the results confirm that VATS lobectomy is associated with a statistically significant shorter
LOS, similar mortality and complication rates and similar rates of lymph node removal in patients with clinical
stage I NSCLC.
Introduction
The routine use of video-assisted thoracic surgical
(VATS) lobectomy for the treatment of resectable non-
small cell lung cancer (NSCLC) remains controversial.
Data supporting the use of VATS lobectomy come from
randomized trials [1-4], a multicenter phase II study [5],
case-control series and large retrospective series [6].
Meta-analyses have recently been published [7,8]. The
randomized trials enrolled relatively small numbers of
patients and retrospective case series are subject to
selection biases. Other recent publications have been
case-control series [9,10].
Most case-control techniques attempt to decrease the
effect of selection bias when comparing two non-rando-
mized treatment groups by analyzing patients that are
“matched” based on preoperative variables that are
known to affect the outcomes that are being studied. It
can be difficult to find appropriate control patients for a
case matching study unless a large control population is
available. Even then, cases without an appropriate match
in either the control or treatment groups are not usable
for analysis. At times, eliminating the cases that cannot * Correspondence: walter.scott@fccc.edu
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tion bias, casting doubt on the conclusion that differ-
ences in outcomes between the two groups are due to
treatment effects [11].
Propensity score based weighting is a rigorous statisti-
cal technique for making nonrandomized comparisons
that in theory allows all of the patient data to be used
from two treatment groups. We used this method to
adjust for selection differences between two patient
populations with clinical stage I NSCLC who underwent
lobectomy performed through either an open or VATS
technique. We then compared the perioperative out-
comes of the two adjusted groups.
Methods
Approval for this retrospective data analysis of prospec-
tively collected data was obtained from the Institutional
Review Board. Patients with known or suspected clinical
stage I NSCLC who underwent surgical resection at Fox
Chase Cancer Center (FCCC) during two periods of
time, from mid-2003 until November, 2005 and from
November 2005-through 2008 were analyzed. Patients
undergoing lobectomy, bilobectomy or segmentectomy
were included. During the study periods, patients under-
went standard preoperative staging with chest computed
tomography (CT) and positron emission tomography
with CT (PET/CT). At the time of the study, brain MR
was performed in patients with neurologic symptoms or
for patients with T2 tumors. Cervical mediastinoscopy
was performed selectively for patients with abnormal
lymph nodes on any imaging study, or for those with
T2 or more central tumors.
All of the operations in this series were performed by
as i n g l es u r g e o n( W J S ) .S t a n dard anesthetic manage-
ment with single lung ventilation including restriction of
intraoperative fluids was used in all patients. Open thor-
acotomy (THOR) was most commonly performed
through a posterolateral incision with entry into the
chest through the fifth intercostal space. Resection of a
small portion of the 6
th rib was routine. Muscle sparing
incisions were used occasionally and rib resection was
not performed in those instances. VATS lobectomy
(VATS) was performed using three incisions, a 5 cm or
smaller access thoracotomy and two additional 1 cm
incisions. Rib spreading and rib resection were not per-
formed. Visualization was achieved using the video
thoracoscope.
Lymph node dissection was routinely performed in all
cases (THOR or VATS). Postoperative pain control was
achieved using patient-controlled analgesia delivered
through thoracic epidural catheters (PCEA) or through
the use of patient-controlled intravenous narcotics
(PCA). Most recently, pain control for VATS lobec-
tomies consists of PCA narcotics supplemented with a
continuous local anesthetic infusion (0.2% ropivacaine)
though subpleural catheters placed intraoperatively.
Patients converted from VATS to thoracotomy were
included in the VATS group. All complications were
graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version
3.0 [12].
Patients undergoing thoracotomy (open cases) were
the control population and patients undergoing VATS
procedures comprised the treatment group. The baseline
characteristics of the two groups are shown in table 1
(demographics). The endpoint of the study was post-
o p e r a t i v el e n g t ho fs t a y( L O S ) ,d u r a t i o no fc h e s tt u b e
placement, and overall complication rates. Because this
was a nonrandomized comparison of two treatments,
the two groups were adjusted for characteristics that
were known to influence the main study outcomes. We
chose age, sex, the preoperative FEV1 percent predicted
and two additional measures, the Charlson Comorbidity
Index (CCI) and the American Society of Anesthesiology
(ASA) score. (Table 2) The CCI consists of the sum of
weighted scores for 19 medical conditions that have
been shown to affect mortality. The CCI has been vali-
dated in a surgical population of lung cancer patients
[ 1 3 ] .T h eA S As c o r ei sar a t i n gs c a l eu s e db ya n e s t h e -
siologists to estimate the overall condition of a patient
in the preoperative period Table 3 [14].
In order to adjust for baseline differences between
those patients who did and did not have VATS, we used
propensity score based adjustment through propensity
score based weighting [15]. Similar propensity score
based weighting has been used in a variety of settings to
investigate treatment effects using observational data
[16,17]. The propensity scores, which are the probabil-
ities of receiving VATS given potential confounders of
Table 1 Charlson Comorbidity Index (CCI)
Score Condition
1 Coronary artery disease
a
Congestive heart failure
Chronic pulmonary disease
Peptic ulcer disease
Peripheral vascular disease
Mild liver disease
Cerebrovascular disease
Connective tissue disease
Diabetes mellitus
Dementia
2 Hemiplegia
Moderate to severe renal disease
Diabetes with end-organ damage
Any prior tumor (within 5-years of diagnosis)
b
Leukemia
Lymphoma
3 Moderate to severe liver disease
6 Metastatic solid tumor AIDS (not only HIV positive)
Adapted from Birim O, EJCTS 2003 with permission
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logistic regression. The adequacy of the propensity score
model was verified by examining adjusted differences in
potential confounder variables between the treatment
groups. The lack of significant differences in propensity-
score adjusted averages of the confounder variables sug-
gested that they could not be confounders after
adjustment.
We used Fisher’s exact tests and T-tests to assess unad-
justed differences. For inferences concerning length of
stay and time until chest tube removal, we used Cox pro-
portional hazards regressions weighted by the inverse of
the probability of receiving the treatment actually
received. The weight would be the inverse of the propen-
sity score for those in the VATS group and the inverse of
one minus the propensity score for those in the thoracot-
omy group. The bootstrap [18] with 2500 resamples was
used to calculate the standard errors. Cox models were
used for the time to event variables since some patients
were lost to follow-up (for example, discharged with a
chest tube) and hence had censored data. We used sim-
ple linear regressions similarly weighted by the inverse of
the probability of receiving the treatment actually
received for adjusted inferences concerning the number
of lymph nodes removed and the number of lymph node
stations sampled. We used propensity score based
weighted logistic models for adjusted inferences concern-
ing complication rate differences.
Results
The study population consisted of 136 patients with
clinical stage I NSCLC. There were 62 patients from
2003 through late-2005 who underwent lobectomy per-
formed through an open thoracotomy and 74 patients
who underwent VATS lobectomy from late 2005
through mid-2008. Patient demographics are shown in
Table 1. There were more men in the group undergoing
thoracotomy and the VATS group had slightly better
pulmonary function based on preoperative FEV1 (% pre-
dicted). There were no significant differences between
groups with respect to clinical stage, pathologic stage
and histology (Table 4). There were no significant differ-
ences between groups with respect to the type of lobect-
omy performed (Table 4). Conversion of a VATS
lobectomy to an open procedure occurred in 3/74 (4%)
of patients. This generally involved enlargement of the
access thoracotomy and placement of a small retractor,
and then performance of the lobectomy with standard
techniques. These patients were included in the VATS
group for the purpose of analysis.
Adjusting for observable differences between cohorts
and balancing important covariates using propensity-
score weighting resulted in two well-matched groups for
analysis (Table 5). The perioperative results and analyses
were based on comparison of data from the adjusted
groups. Patients undergoing VATS lobectomy had a
shorter length of stay (VATS, 4 days versus THOR, 7
days, p < 0.001, HR = 0.33 in favor of VATS). Patients
Table 2 Patient Characteristics, Unadjusted data, % or
mean (SD)
Thoracotomy
n=6 2
VATS
n=7 4
p-value
Male 47% 30% 0.054
FEV1% pred 79 (19) 85 (19) 0.040
CCI 1.7 (1.3) 1.7 (1.3) 0.982
Age 65 (10.3) 67 (10.9) 0.489
ASA 2.3 (0.6) 1.8 (0.7) <0.001
Table 3 American Society of Anesthesiologist (ASA) Score
Class 1 Healthy patient, no medical problems
Class 2 Mild systemic disease
Class 3 Severe systemic disease, but not incapacitating
Class 4 Severe systemic disease that is a constant threat to life
Class 5 Moribund, not expected to live 24 hours irrespective of
operation
An e is added to the status number to designate an emergency
operation.
An organ donor is usually designated as Class 6
Table 4 Details of Surgical Procedures
Open lobe
(n = 62)
VATS lobe
(n = 74)
P value
Histology
Adeno 44 71% 50 68% 0.898
Squamous 9 15% 12 16%
Other 9 15% 12 16%
Clinical stage
IA 49 79% 65 88% 0.242
IB 13 21% 9 12%
Pathologic stage
IA 32 52% 45 61% 0.165
IB 20 32% 12 16%
II 5 8% 7 9%
III, IV 5 8% 10 14%
Type of resection
RUL 20 32% 23 31% 0.168
RML 3 5% 10 14%
RLL 8 13% 12 16%
LUL 18 29% 14 19%
LLL 10 16% 10 14%
Bilobectomy 3 5% 1 1%
Segmentectomy 0 0% 4 5%
Scott et al. Annals of Surgical Innovation and Research 2010, 4:1
http://www.asir-journal.com/content/4/1/1
Page 3 of 6in the VATS group also had their chest tubes removed
earlier (VATS, 3 days versus THOR, 5 days, p < 0.0001,
HR = 0.42 in favor of VATS). The number of lymph
node stations dissected in the VATS and THOR groups
was similar (4.6 stations versus 4.3 stations, respectively,
p = 0.31) as was the total number of lymph nodes
examined in the specimen (18.1 versus 14.8, p = 0.17).
Mortality rates were similar, with 1/74 (1.4%) in the
VATS group and 1/62 (1.6%) in the THOR group
(p = 1.00).
Perioperative and postoperative complications were
classified and graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events ver-
sion 3.0 (Table 6). No differences in complication rates
were noted for either cohort (VATS or THOR). No
complications were recorded for 40/62 (65%) THOR
patients compared to 52/74 (70%) of VATS patients
(p = 0.61). There was a trend suggesting a decrease in pul-
monary complications in the VATS group 10/74 (14%)
compared to the THOR group 20/62 (32%) (p = 0.10).
Continuous heart rate monitoring was routine during the
second period of the study when VATS lobectomy was
initiated. Therefore the low number of arrhythmias in the
THOR patients may reflect the fact that only those
arrhythmias that were persistent or were associated with
symptoms were recorded for those patients, whereas even
brief periods of atrial fibrillation were detected and
recorded for the VATS group.
When complications were examined by age (70 years
and older){Table 7), the trend toward a decrease in pul-
monary complications associated with VATS was pre-
sent but still did not reach statistical significance,
perhaps because of the small number of patients in each
group.
Discussion
We used propensity score based weighting to perform a
non-randomized comparison of patients who underwent
wither open thoracotomy and lobectomy or VATS
lobectomy for clinical stage I NSCLC. The statistical
method that we used generates an adjusted population of
patients whose outcomes are slightly different that the
observed data. For example, that is the reason that the
complication rates in Table 8 (39% for THOR and 34%
for VATS) are slightly different than the unadjusted com-
plication rates in Table 6 (35% for THOR and 30% for
VATS). The adjusted rates are based on a larger number
of patients and therefore should be considered the most
generalizable data. After balancing the two cohorts based
on preoperative covariates known to influence periopera-
tive outcomes using propensity score based weighting,
we found that patients undergoing VATS lobectomy for
clinical stage I NSCLC had their chest tubes removed
earlier (adjusted median 3 days versus 5 days, p < 0.001)
and also had a shorter postoperative length of stay
(adjusted median 4 days versus 7 days, p < 0.001)) than
patients undergoing open thoracotomy. This is consistent
with what others have observed from case control series
[9,10] and large retrospective case series [6]. Patients
undergoing VATS lobectomy may experience less pain,
have improved respiratory mechanics, and develop less of
an inflammatory response compared to open thoracot-
omy, all of which combined may lead to a decreased
postoperative length of stay.
Despite the marked reduction in postoperative length
of stay, we found no statistically significant difference in
overall complication rates or specific complication rates
between VATS patients and THOR patients. One reason
for this is that the number of episodes of atrial
Table 5 Patient Characteristics Adjusted Data, N = 136
Thoracotomy
n=6 2
VATS
n=7 4
Male 40% 39%
FEV1% pred 80 (19) 81 (20)
CCI 1.6 (1.3) 1.7 (1.3)
Age 66 (10) 66 (11)
ASA 2.1 (0.6) 2.1 (0.7)
Table 6 Complication Rates
Complication Open N = 62
Unadjusted data
VATS N = 74
Unadjusted data
P value (unadjusted) P value
(adjusted)
None 40 (65%) 52 (70%) 0.58 0.61
Pulmonary 20 (32%) 10 (14%) 0.01 0.10
Cardiac-arrhythmia 2 (3%) 10 (14%) 0.07 0.71
Hemorrhage 1 (2%) 4 (5%) 0.38 0.88
Other 1 (2%) 2 (3%) 1.00 0.98
Table 7 Complication rates in patients aged 70 and older
Complication Open N = 22 VATS N = 30 P value (adjusted)
None 14 (64%) 21 (70%) 0.77
Pulmonary 7 (32%) 3 (10%) 0.08
Cardiac-arrhythmia 2 (9%) 5 (17%) 0.69
Hemorrhage 0 (0%) 1 (3%) 1.00
Other 0 (0%) 1 (3%) 1.00
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mated since routine use of postoperative heart rhythm
monitoring was phased in during the first part of the
study when the open lobectomy operations were per-
formed. Therefore, it is likely that episodes of atrial
fibrillation in this group were missed and that the true
rate of atrial fibrillation in this group was much higher.
This would have increased the overall and arrhythmia
complication rates in the THOR group. Other studies
have suggested that atrial fibrillation rates after VATS
lobectomy are not different than after thoracotomy and
lobectomy [8,9].
Mortality rates were not different between groups in
our study. We did observe a trend (p = 0.10) toward a
decrease in respiratory complication rates in the VATS
patients, especially in the 70 year and older group, with
the rates of respiratory complications decreasing from
32% in the open group to 10% in the VATS group (p =
0.08). A decrease in respiratory complications in older
patients undergoing VATS lobectomy compared to
THOR was observed by Cattaneo et al. [10]. It is possi-
ble that a statistically significant difference in respiratory
complication rates would have been observed in our
study if the sample size had been larger.
Regarding oncologic efficacy of VATS compared to
THOR, we found that all patients underwent compete
resections with negative margins. The number of lymph
node stations that were dissected and the total number
of lymph nodes retrieved were similar for each group.
C o n t i n u e df o l l o wu pw i l lb er e q u i r e dt od e t e r m i n e
oncologic efficacy of VATS compared to THOR.
The limitations of this study include its retrospective
nature, the fact that management changes may have
occurred over the study period that were not appre-
ciated or reflected in the analysis (such as the change to
continuous heart rate monitoring or other changes in
postoperative management), and the sample size. The
fact that is not a multicenter study is mitigated by the
fact that our conclusions, while analyzed somewhat dif-
ferently, are similar to those of other authors. The
strengths of the study include the fact that all cases
w e r ep e r f o r m e db yas i n g l es u r g e o n ,i ti sac o n s e c u t i v e
case series, and that covariates were balanced between
the two cohorts using sophisticated statistical analysis.
Conclusion
In summary, we found that patients undergoing VATS
lobectomy were able to have their chest tubes removed
sooner and were discharged sooner after undergoing
lobectomy for clinical stage I NSCLC than patients who
underwent thoracotomy and lobectomy for the same
indications. A trend toward a decrease in pulmonary
complications in the VATS group was also observed,
especially in patients 70 years of age or older. The use
of propensity score-based weighting in this series and its
application to larger databases will allow clinicians to
draw stronger conclusions about the relative merits of
VATS lobectomy versus open thoracotomy and lobect-
omy in the treatment of the patient with early stage
lung cancer.
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Table 8 Perioperative Results, Adjusted Data
Op. N Peri-op
mortality
(%)
Length of
Stay
(Adjusted
median
days)
Chest tube removal
(Adjusted median
days)
Adverse Events (Adjusted %
of patients with at least
one)
Lymph Node Stations
(Adjusted # sampled/
patient)
Lymph Nodes
(Adjusted mean #
removed/patient)
Thor 62 1 (1.6%) 7 5 39% 4.6 18.1
VATS 74 1 (1.4%) 4 3 34% 4.3 14.8
HR = 0.33 HR = 0.42
P-value P = 1.00 P < 0.0001 P = 0.0001 P = 0.61 P = 0.31 P = 0.17
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